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Organogenesis in embryonic life constitutes a series of intricate
processes that involve differentiation and rapid proliferation of
pluripotent cells leading to the formation of a defined structural-
ized tissue mass, and is followed by a continuum of cell replication
and terminal differentiation in most mammalian organs, with few
exceptions, such as nervous system. These processes are modu-
lated by various extracellular matrix (ECM) glycoproteins [1],
ECM receptors, that is, integrins [2], cell adhesion molecules
(CAMs) [3], intracellular cytoskeletal proteins [I, growth factors
or hormones and their receptors [5], DNA-binding proteins [6],
proto-oncogenes [71, and ECM degrading enzymes and their
inhibitors [8]. The activities of this diverse group of macromole-
cules in embryonic development are interwoven. For instance,
ECM glycoproteins influence the intracellular events via their
receptors, that is, integrins, and thereby, cell differentiation,
migration and polarization. On the other hand, the transcription,
translation and post-translational modification of ECM macro-
molecules has been shown to be regulated by various growth
factors or hormones and their receptors, and the latter may be
encoded by proto-oncogenes. Along with cell:matrix interactions
[9], another set of macromolecules, CAMs, which influence
intercellular adhesion and cell:cell (homotypic or heterotypic)
interactions, also influence morphogenesis of various organs.
Finally, critical to cell behavior during differentiation associated
with organogenesis is the fundamental process of phosphoiylation
of various integrins and hormone- or growth factor-receptors and
proto-oncogenes, which contain tyrosine or serine/threonine ki-
nase intracellular catalytic domains [10, 11].
During embryonic development, there is considerable variabil-
ity in the cellular events and in the expression of various macro-
molecules, which are pre-determinants (required) for the forma-
tion of individual organ systems. For instance, the expression of
various ECM glycoproteins varies considerably in different devel-
oping organ systems. This would suggest that the macromolecules
with restricted genotypic or phenotypic expressions are relevant
only to the morphogenesis of a particular organ system. Thus, "a
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morphogen is defined as a molecule that expresses its concentration
gradient in a given tissue and alters the fate of target cells in a
dose-dependent manner." This definition of a morphogen is appli-
cable not only to ECM macromolecules but also to their respec-
tive receptors, that is, integrins, CAMs, growth factors and their
receptors and proto-oncogencs. In the same vein, differential
concentration gradients of these macromolecules in various re-
gions of the same developing tissue would induce different specific
cellular events, thus adding complexity to the differentiation
processes that ultimately lead to regional specialization within a
given organ system, Finally, the magnitude of expression of
various morphogenetic elements during fetal life suggest that
their function is specific for a given stage of a developing organ
system. Although the expression of morphogens is stage and tissue
specific, a concerted coordination among the various macromol-
ecules is critical for morphogenesis to proceed normally in the
formation of a particular visceral organ.
Information on the role of morphogenetic modulators has been
derived from the in vivo knock out experiments in mice as well as
in vitro culture systems applicable to mammary [12], prostate [13]
and salivary glands [14], lung [15] and kidney [16, 17]. With
respect to morphogenesis, there are features common to these
organ systems, such as epithelial:mesenchymal/ligand:receptor
interactions, as well as differences in other aspects. These differ-
ences are somewhat unique to the development of the mammalian
metanephros, and this review addresses some of the distinct
features relevant to renal development and its regulation by ECM
and their receptors, growth factors, proto-oncogenes and tran-
scription factors.
GENERAL FEATURES OF METANEPHRIC DEVELOPMENT
Nephrogcnesis commences with the successive appearance of
the pronephros, mesonephros and mctanephros as a craniocaudal
wave of cellular differentiation in the nephrogenic cord lying
alongside the nephric or Wolffian duct [16]. In mammals, the
pronephros and mesonephros are vestigial elements of the neph-
rogenic cord, and their appearance is transitory, while the meta-
nephros matures to form a permanent kidney. Metanephrogenesis
ensues at days 10 to 11 of fetal life in the mouse and at about the
5th week of gestation in humans [18]. The metanephros is formed
by the interaction of the dorsally migrating ureteric bud, an
epithelial-lined tubular structure arising from the Woiffian duct,
with the blastema, a loosely organized mesenchymal mass on the
lateral aspect of the aorta in the most caudal segment of the
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Fig. 1. Schematic drawing depicting various stages of differentiation of
the nephron. Formation of the nephron commences by interaction of the
ureteric bud with loose metanephric mesenchyme. As a result, a conden-
sate is formed, which goes through the comma-shape and S-shape body
stages. This is followed by tubule elongation to form the precapillary stage
nephric unit. The precapillary unit is vascularized by an ingrowth of
extra-renal blood vessels leading to the formation of a mature glomerulus
with an intricate capillary network (modified and reprinted with permis-
sion from [17]).
nephrogenic cord. The migratory collision of the ureteric bud with
the blastema is followed by a series of events leading to differen-
tiation of the mesenchyme, arborization of the ureteric bud and
the generation of nascent nephrons. The latter upon vasculariza-
tion by the processes of vasculogenesis and angiogenesis forms
functional nephric units of the kidney [161. These differentiation
processes are further elaborated upon in the following section.
The invasion of the ureteric bud induces the mesenchymal cells
to aggregate around its advancing edge (Fig. 1). The process of
aggregation of the mesenchymal cells is prototypic of homotypic
interactions, that is, between similar cell types, while intercalation
of the ureteric bud into the mesenchyme typifies heterotypic
interactions between dissimilar cell types. With mesenchymal cell
aggregation, there is an increased adhesiveness and approxima-
tion of cells with the formation of condensates in the cortical
region of the blastema. Initially, the uninduced mesenchyme and,
subsequently, the induced mesenchyme reciprocally stimulate the
iterative dichotomous branching of the ureteric bud. The latter
elongates centrifugally into the peripheral cortex, the nephrogenic
zone of the metanephros. Incidentally, such mesenchymal-in-
duced branching morphogenesis is also paradigmatic to the
organogenesis of lungs and salivary, breast and other urogenital
glands, that is, prostate [12—15]. At the tips of the elongated
ureteric bud branches, the genesis of nascent nephrons ensues
whereby the "precommitted" and induced-mesenchyme is trans-
formed into epithelial condensates or vesicles. With this inductive
neotransformation there is a gradual loss of certain mesenchymal
proteins, that is, interstitial collagens (type I and Ill) [19],
fibronectin [201, neural cell adhesion molecules (N-CAM) [21]
and intracellular vimentin [22]. At the same time, there is a steady
increase in the expression of other glycoproteins, such as cytoker-
atm [22], basal lamina collagens IV and V [20], laminin-A chain
[23, 24], proteoglycans [25, 26] and E-cadherin or uvomorulin
[27]. The latter, a cell adhesion molecule, is an avian homologue
of L-CAM derived from the chicken liver. Such changes are not
restricted to cellular and matrix proteins, but are also seen in
various growth factors, their receptors, proto-oncogenes and
transcription factors during the epithelial neotransformation of
metanephric mesenchyme.
Following these phenotypic changes, the condensate undergoes
a regional caveolization in the epithelial cell mass near the
ureteric bud branch while an invagination appears near its lower
pole. As a result a hollow comma-shaped body is formed with a
labiate fold at the lower pole of the condensate, which is situated
at the opposite end from the ureteric bud. In the following stage,
there is canalization of the lip, elongation of the hollow tube and
appearance of another indentation or crevice near the upper pole
which is opposite in orientation of the previous one. Thus, the
hollow tube becomes more convoluted, perhaps due to differen-
tially timed asymmetric cellular adhesive gradients at the opposite
poles, and thus, an S-shaped body is formed. Conceivably, the
development of polar gradients may also be related to the
differential targeting of the growth factors, their receptors and
proto-oncogenes leading to an asymmetrical growth and regional
specialization within the S-shaped body nephric unit [16]. The
distal (lower) portion of the S-shaped body develops into a
glomerulus, while the upper (proximal) portion forms more
polarized epithelia, that is, the proximal and distal tubules, which
ultimately fuse with collecting ducts derived from the ureteric bud
branches. Exactly how the fusion of the blind ends of distal
tubules and ureteric bud branches occurs is unknown. Perhaps the
canalicular continuity is established by local enzymatic degrada-
tion of the basal lamina of the two blind ends accompanied with
apoptosis of the cells lining them.
In the S-shaped-body stage, bilayered epithelium at its lower
pole can be readily recognized. Its peripheral or parietal layer,
made up of flattened cells, forms the Bowman's capsular epithe-
hum that is continuous with the proximal tubular epithelium. The
inner layer, facing the concave aspect of the indentation, matures
into highly specialized epithelial cells, known as podocytes. Im-
mature podocytes have a columnar shape and rest upon the basal
lamina of the ECM surrounding the hollow coiled tubules of the
S-shaped body. With progressive replication of the podocytes in
the S-shaped body, the precapiila#y stage ensues. The apical
portion of the primitive podocytes are held in contact with one
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another via tight junctions. With the evolution of the precapillary
stage, the cells mature, become cuboidal, lose some of the
plasmalemmal lectin binding affinities, that is, glycoconjugates
[281, and acquire other cell-surface associated sialoglycoproteins
[291, such as podocalyxin [30]. The latter conceivably has trans-
membrane connections with intracellular cytoskeletal proteins
and participates in the differentiation of epithelial foot processes
at the basal aspects of the podocytes apposed to the scaffold of
ECM. During these maturational events, the podocytic apical
tight junctions descend along the sides of the differentiating foot
processes and form ladder-like structures, known as slit dia-
phragms. The latter are connected to the outer leaflets of the
plasmalemma of the foot processes, and contain tight junctional-
specific protein, that is, ZO-1 [311. The podocalyxin and some of
the other glycoproteins, such as p51, also become concentrated
either on the urinary (podocalyxin) or capillary (p51) aspect of the
slit diaphragm of the newly formed podocytic foot processes [32].
The time period, encompassing the appearance of early conden-
sates to fully differentiated tubular epithelia with well-defined
polarity characteristics, is also accompanied with the expression of
some of the desmosomal intercellular junctional proteins, includ-
ing desmoplakins and desmocollins [331.
At the S-shaped body stage, a few rudimentary blood vessels are
observed in the vicinity of its lower indentation or crevice. These
blood vessels represent future afferent and efferent arterioles of
the nascent nephrons, and their endothelial sprouts are drawn
into the cleft under the influence of mitogenic, angiogenic or
chemotactic factor(s) [34]. With progressive invasion by the
endothelial sprouts and perhaps along with recruitment of local
cells, an anastomosing capillary network is established, and
thereby the precapillary elements of the nephrons are vascular-
ized to form a mature glomerulus. In the formation of a capillary
network, the migratory endothelium, invested with its own ill-
defined ECM scaffold, interacts with the pre-existing basal lamina
of the podocytes. The newly formed basal lamina is initially
bilayered, and apparently is derived from both the epithelial and
endothelial cells [35]. However, in a mature glomerular capillary,
the two layers fuse, and at the same time undergo segmental
splicing and addition of an ECM scaffold with the formation of a
uniform electron-dense layer, known as the lamina densa of the
glomerular basement membrane (GBM) [36]. The dual cellular
origin of the GBM has been established by metabolic studies [37],
histochemical and immunohistochemical techniques [25, 26], and
by inter-species chimeric grafting experiments [38]. In the chi-
meric experiments, the mouse or chick metanephric explants
grafted onto the quail chorioallantoic membrane became vascu-
larized by the endothelium and synthesized species-specific ECM
components. These experiments also established that the angio-
genesis of the metanephros ensues by the migration of the
extra-renal blood vessels. However, recent ocular graft experi-
ments, using immunohistochemical markers indicate that the
endothelial precursor cells (angioblasts) are present within the
mesenchyme, and that they are responsible for the vasculogencsis
of the kidney [39]. Thus, it seems that in the vascularization of the
metanephros and capillarization of the glomerulus, both the
processes of vascularization as well as angiogenesis are essential.
A third cell type known as the mesangial cell is located in the
intercapillary regions of the mature glomerulus [40], and its
developmental origin remains unclear. However, quail/chicken:
mouse chimeric experiments suggest that the metanephros is
populated with mesangial-like cells derived from the migratory
endothelium [38]. Lastly, the ontogeny of the juxtaglomerular
cells is not entirely clear, and needs to be investigated.
All the stages of glomerular development can be visualized in a
histological section of the newborn murine kidney, where the
immature nephrons are beneath the renal capsule while the most
mature nephrons are in the deeper cortex (Fig. 2A). To gain
insights into the developmental dynamics of the metanephros,
investigators have resorted to in vitro techniques, including organ
or cell culture systems. The cell culture system, such as MDCK
cell lines, have been useful in studying the morphogenesis of
tubules and the development of their epithelial junctions and
polarity characteristics [41]. To study the morphogenesis of the
whole kidney and of the glomerulus and tubules, Grobstein [42,
43] established an in vitro metanephric organ culture transfilter
technique, which has been used widely with certain modifications
[44, 45] for four decades by numerous investigators. In this culture
system, various developmental stages, with the exception of
vascularization of the metanephros, can be studied (Fig. 2B). The
technique employs harvesting of either uninduced (day 10½) or
induced (day 11½) metanephric mesenchyme, placing it on the
top of a microporous (— 0.8 m) filter and maintaining it in
culture for 7 to 10 days. In this system, the uninduced mesen-
chyme can be induced by placing ureteric bud or a heterologous
inducer, such as embryonic neural tissue, on the bottom of the
filter. The metanephric mesenchyme receives the inductive signals
through the pores of the filter, perhaps by establishing pseudopo-
dial cell-cell contacts [16]. Once the mesenchyme is induced,
morphogenesis of the nephrons proceeds normally even if the
inducer is removed after only a brief exposure of about 24 hours
[16]. The induced mesenchyme goes through a series of differen-
tiation events leading to glomerulo- and tubulo-genesis. Finally,
fundamental to the inductive neo-transformation of the mesen-
chyme are the molecules expressed at the epithelial:mesenchymal
interface or ligands expressed in the mesenchyme and receptors in
the ureteric bud epithelium, which would be ideally suited for
paracrine/juxtacrine interactions (Fig. 3). The concept of such
uxtracrine/paracrine interactions in nephrogenesis is emphasized
in the various sections of this review, and is well-supported by
recent studies with the in vitro metanephric culture techniques
and in vivo knock-out experiments in the mouse.
ECM, INTEGRINS, ECM-DEGRADING ENZYMES AND
CAMS
In the early sixties Saxen and Grobstein [16, 42] postulated a
"paracrine" effect for the basement membrane (BM) of the ECM,
sandwiched between the leading edge of the ureteric bud and the
blastema. This "paracrine" effect facilitates the interactions be-
tween the two cell types and leads to epithelial conversion of the
metanephric mesenchyme. Since the BM glycoproteins that in-
duce branching morphogenesis are cytosecretory products of the
native or neotransformed epithelium, the current belief is that
basal lamina also has a self-stimulatory or "autocrine" effect on
the embryonic tissues during development. Although the impetus
for these studies evolved from the initial detection of constitu-
tively expressed BM glycoproteins in the metanephric tissues,
their simple presence and expression may not have a specific role
at a given stage of embryonic development. Nevertheless, many
studies have conclusively elucidated the morphogenetic role of
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Fig. 3. Schematic drawing depicting the reciprocal induction of mesen-
chymal cells and ureteric bud epithelia in embryonic kidney. The recep-
tors of growth factors (GFs) and of extracellular matrix (ECM), that is,
integrins, are localized in the epithelial cells of the ureteric bud. The
proto-oncogenes, such as, c-ret and c-ros, which function as tyrosine kinase
receptors, are localized in the ureteric bud epithelium. Although the
ligands of many proto-oncogenes are unknown, the ligand of c-ret is a
glial-derived neurotrophic factor (GDNF), and is shown here to be
expressed in the metanephric mesenchyme. Among the ECM proteins,
some are expressed in the mesenchyme, while others are expressed at the
epithelial:mesenchymal interface (modified from [1621; used with permis-
sion).
certain ECM and ECM-related macromolecules in renal devel-
opment [16, 17].
Extracellular matrix macromolecules and matrix-degrading
enzymes
Fig. 2. (A) Photomicrograph of a section of a newborn mouse kidney
stained with anti-proteoglycan antibody, showing successive stages of
glomerular development, that is, vesicle (v), comma shaped.body (c),
S-shaped body (s), precapillary (p) and capillary (C). The immature
nascent nephrons are formed in the superficial cortex, that is, the
nephrogenic zone, and with maturation they become localized to the
deeper cortex (from [261, with permission). (B) Photomicrograph of a
metanephric explant maintained in an in vitro organ culture, showing
urcteric bud branches (U) and formation of various nephron elements in
the nephrogenic zone.
Among the various ECM molecules expressed during meta-
nephric development are mesenchymal proteins (that is, intersti-
tial collagens, tenascin and fibronectin) and integral BM glyco-
proteins (type IV collagen, lam mm and proteoglycans) [46]. Some
of the mesenchymal proteins, such as interstitial collagens, disap-
pear at day 11 after induction, while the mRNA expression of
others, such as of the splice variants of fibronectin EI1IA, EII1B
and V, decreases rapidly after day 15/16 of murine gestation [47].
Although mesenchymal proteins are expressed in the metane-
phros, their role remains elusive since anti-fibronectin antibodies
are incapable of perturbing the conversion of mesenchyme to
polarized epithelium, and although the RGDS peptides that bind
to the fibronectin receptor reduce lobulations of embryonic lungs
[46], they are ineffective in inhibiting metanephrogenesis [48].
Also, no nephric defects in mice lacking fibronectin have been
described [49]. Tenascin is another mesenchymal protein that
interacts with fibronectin and proteoglycans, and it appears
transiently around the condensates, S-shaped bodies and tubules.
Although its expression decreases if tubulogenesis is inhibited
[50], no renal defects have been described in tenacin deficient
knock-out mice [51]. In contrast to the limited functional data on
the mesenchymal proteins, the role of integral BM glycoprotcins
(type-IV collagen, laminin and proteoglycans) is more well-
defined in embryonic development. They seem to appear simul-
taneously around the condensate, S-shaped bodies, glomerular
Mesenchymal cells
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of mesenchyme
Ureteric bud epithelia
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Fig. 4. Control (A) and puromycin-treated (B) metanephric explants radiolabeled with [35S] -sulfate, a precursor product of sulfated proteoglycans
(PGs). The control shows radioactivity (arrows) concentrated at the tips of ureteric bud branches, that is, at the epithelial:mesenchymal interfaces.
Puromycin treatment leads to a disorganization of the ureteric bud branches associated with a loss of radioactivity (from [56, 611; used with permission).
Control (C) and IGF-I-treated (D) metanephric explants. The IGF-I-treated explant exhibits a trophic response (from [991). Control (E) and IGF-I
receptor antisense-treated (F) explants. The explant treated with IGF-IR-antisense shows marked growth retardation (from [97, Control (G) and
c-ret antisense-treated (H) explants. The explant treated with c-ret antisense exhibits branching dysmorphogenesis of the ureteric bud and marked
atrophy of the metanephric mesenchyme. Conceivably, these changes reflect perturbed epithelial:mesenchymal interactions, which ultimately lead to
hypogenesis of the embryonic kidney (from [1621).
capillaries and around the tubules [201, however, the expression of
their individual peptide chains is asynchronous.
The role of laminin, a high molecular weight protein with A, BI
and B2 chains organized into a cross-shaped structure, has been
well established [52]. Under the new nomenclature they are
referred to as cr11, 131 and yl laminin chains, respectively [53]. The
expression of laminin chains during early development is asyn-
chronous, and is also species- and stage-specific [46]. The mRNA
expression of (31 and yl laminin chains is detectable in vitro 24
hours after the induction of nephrogenesis in mice. In contrast,
the expression of cr1 chain appears only after two days, coinciding
with the appearance of polarized epithelia in the comma and
S-shaped bodies, and is gradually lost from the ureter, distal
tubules and glomerular basement membranes. Evidence for a
direct role of laminin in vitro nephrogeriesis was elucidated by
using elastase-generated peptides and chain specific antibodies,
that is, against the carboxy ends of cr1- (E3) and crl-(31-yl (E8),
the amino terminus of /31-chains (E4), and the central region of
the whole laminin molecule containing the YIGSR-dependent
laminin receptor binding sites [46]. The antibodies against E3, the
heparin binding domain, and E8, the a6(31 integrin receptor
binding site [54], inhibited the morphogenesis and formation of
polarized epithelium, while antibodies against the central region
of the laminin molecule did not perturb the renal development
[46]. Interestingly, the antibodies directed against the central
regions of laminin do perturb morphogenesis of the lungs [46].
During development, other roles of laminin include angiogenesis
and integrin-receptor mediated attachment, with the activities
confined to YIGSR sequences of laminin /31 and RGD sequences
of cr1 chain, respectively [52]. The expression of cr1 chain is
observed only in larger blood vessels of various fetal organs [46].
The differential expression of these chains may also be related to
the emergence of laminin cr1 and /31 chain isoforms or variants
like merosin (Am or cr2) and S-laminin (B1 s or /32), respectively
[52]. The /32 has been identified in mature glomeruli and in
capillaries of other tissues. Such stage-specific isoforms or
switches in their expressions are also seen in other proteins that
regulate development, such as type-IV collagen and proteogly-
cans.
The role of proteoglycans (PGs) has been elucidated in several
tissues [55]. PGs are heterogeneous macromolecules, and are
made up of glycosaminoglycan (GAGs) chains that are bound by
0-glycosidic linkage to the core-peptide. A number of different
types of PGs are expressed in the kidney, and include, heparan
sulfate-proteoglyean [56], chondroitin sulfate-proteoglycan (CS-
PG) [57], decorin and biglycan [58]. The basal lamina specific
HS-PG is known as perlecan [59], while those that are cell
membrane bound belong to the family of syndecans [60]. The
syndecans are present in the mesenchyme and early differentiating
epithelium, and they gradually disappear with the maturation of
the nephron [60]. Initially at the time of induction, the sulfated
PGs are highly concentrated at the tips of the ureteric bud
branches: the epithelial:mesenchymal interface and the site where
nascent nephrons are formed (Fig. 4A). Later on, they are seen
around the condensate and persist in the BMs throughout the
fetal and neonatal periods [56]. Inhibition of synthesis of sulfated
PGs by puromycin or addition of GAG chains onto the core-
peptide is associated with blunting of the tips of ureteric bud
branches and dysmorphogenesis of the kidney (Fig. 4B) [56, 61].
Incidentally, the addition of heparin sulfate, and not heparan
sulfate, to culture medium also inhibits nephrogenesis [62]. Thus,
it appears that the biological actions of PGs are mediated via their
GAG chains, and this notion has been supported by the experi-
ments with salivary glands, where elimination of GAGs was shown
to inhibit lobulogenesis [63]. The GAG chains interact with other
matrix molecules, such as the E8 fragment of laminin [54], and
they also act as reservoirs for various growth factors, such as basic
fibroblast growth factor [64], and thus can influence morphogen-
esis by more than one mechanism.
From the above discussion, it seems that a concentration
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gradient of PGs, the highest content being at the tips of the
ureteric bud branches or epithelial:mesenchymal interface, are
necessary to maintain nephrogenesis. A similar concentration
gradient of PGs in salivary glands, that is, cleft versus the
advancing tips, is thought to be responsible for their lobulogenesis
[63]. Such concentration gradients also are observed for other
ECM glycoproteins, such as type-Ill collagen whose expression is
highest in the cleft [65]. These gradients may be due to their
constitutive expression or to a relative local deficiency of degrad-
ing enzymes like collagenase or gelatinase. In the lungs, an
enhanced gelatinase-A (matrix metalloproteinase-2, MMP-2) ac-
tivity, in response to TGF-a and EGF, has been reported to
inhibit arborization of the pulmonary alveoli [661. Conversely,
increased expression of stromelysin-I (MMP-3) correlates with
the accentuated lobulation of the mammary gland [67]. Such
metalloproteinases, including MMP-2, -9, and membrane type-I
(MT-1-MMP), are expressed in the metanephros, and their role in
renal organogenesis has been recently elucidated [68—70]. It is
interesting to note that the mRNA of MT-1-MMP is expressed in
ureteric bud epithelium while that of the MMP-2 is expressed in
the metanephric mesenchyme [70], and such a distribution of
MMPs would be quite conducive for the epithelial:mesenchymal
interactions to take place. Moreover, it seems that it is the
tri-macromolecular complex of MT-1-MMP:MMP-2:TIMP-2 (tis-
sue inhibitor of MMPs) that ultimately influences the morpho-
genesis of the embryonic kidney [70]. Among the serine proteases,
tissue-type plasminogen activator (t-PA) has been localized to
S-shaped bodies and glomeruli, while the urokinase-type (u-PA)
has maximal gene expression in the renal tubular epithelia [71].
Both t-PA and u-PA can degrade ECM either on their own or by
activating latent MMPs. Among the various MMPs, MMP2
displays a transient immunoreactivity in the mesenchymal-derived
condensates and S-shaped bodies. Although these matrix-degrad-
ing proteases are expressed in the embryonic kidneys, the mice
lacking t-PA and u-PA do not reveal any embryological abnormal-
ities [72]. However, in vitro, the tubulogenesis of MDCK cells is
inhibited by the inhibitors of serine proteases whose enzymatic
activities and expression are modulated by a known morphogen,
hepatocyte growth factor [73].
Matrix receptors (integrins), cell adhesion molecules (CAMs)
Integrins. Integrins are transmembrane, heterodimeric, non-
covalently bound glycoprotein complexes consisting of a and 13
chains, and are widely distributed in various tissues, and mediate
diverse biological functions including cell-cell and cell-matrix
interactions, cell polarity, cell migration and angiogenesis [2].
Although both chains participate in divalent cation-dependent
and peptide-sequences-specific ligand binding, the a subunit
largely determines the substrate specificity with ECM glycopro-
teins. The intracytoplasmic tail of p chain is responsible for its
interactions with the cell cytoskeleton via binding to talin, vinculin
and a-actinin, and may be also involved in transductional events
since certain f3 subunits contain tyrosine phosphorylation sites [2].
In the metanephros, the integrin exhibits spatio-temporal expres-
sion. Among the f3 integrins, a1(31 and a4(31 are expressed in the
uninduced mesenchyme, while a3(31, a2131 and aj31 are distrib-
uted at the interface between the basal lamina and the plasma-
lemma of the foot processes of developing podocytes, endothelia
and tubular epithelium, respectively [74, 751 The a6 subunit,
expressed in the cells of the condensing mesenchyme and polar-
ized tubular epithelium, has co-distribution with the laminin a!
chain. The a6(31 integrin serves as the receptor for ES fragment of
al-(31-yl chains of laminin, and like this laminin fragment, anti-
a6 antibodies also perturb the formation of polarized nephric
epithelium and branching morphogenesis of salivary glands and
tuhulogenesis of the metanephros in vitro [46, 76]. The in vivo role
of a8 integrin is most interesting since its gene disruption leads to
an almost complete arrest of nephrogenesis [77]. Although a
target mutation in the integrin a3 gene does not lead to agenesis/
hypogenesis of the embryonic kidney, a certain degree of growth
retardation of the metanephros is observed [78]. Since the ES
fragments also interact with a3f3 and a7!.!1 integrins, suggesting
that their common 13 subunit may also have a functional role in
morphogenesis [74]. In this regard, anti-I.!1 antibodies have been
shown to cause functional impairment in the mammary epithelia,
and block the differentiation of colon carcinoma cells and the
formation of glandular structures in 3-D collagen gels [46]. The
role of f3 in nephrogenesis has received limited attention [76], but
its in vivo gene disruption is associated with pen-implantation
lethality [79]. Among the a-related integrins, af3i has been
reported to be present on the endothelial cells of glomerular and
extraglomerular capillaries [74]. The relevance of aj33 in the
renal angiogenesis remains to be investigated, however, a-reIated
integrins certainly play a role in metanephric development [801.
Cell adhesion molecules (CAMs). CAMs are integral plasma-
lemmal glycoproteins that may be involved in the increased
adhesiveness of cells to form condensates around the ureteric bud
branches during development. Two types of CAMs, that is, neural
(N-CAM) and liver (L-CAM), are expressed in the kidney [81,
82]. The N-CAM, a heavily sialyated glycoprotein, is distributed in
the uninduced mesenchyme. While L-CAM (E-cadherin or uvo-
morulin), a prototype of class I cadherin and a glycosylated
protein with adhesive properties confined to its 26 kDa fragment,
appears subsequent to induction in the condensates and at lateral
surfaces of the differentiated polarized tubular epithelium, it
coincides with the expression of laminin-al chain, thus suggesting
its potential role in tubulogenesis. However, the antibodies to
both L-CAM and N-CAM do not inhibit the conversion of
mesenchyme to an epitheliat phenotype of the metanephros [81,
82], or affect the morphogenesis of MDCK cells [83]. Also,
N-CAM-deficient mice do not exhibit any renal abnormalities
[84]. Incidentally, the anti-uvomorulin antibodies perturb com-
paction at the 8 to 16 cell stage of the primitive embryonic tissues,
which may be due to interference in kinase-C dependent phos-
phorylation [85] and disruption of uvomorulin:actin interactions
mediated via a- and (3-catenins, which associate with the intracy-
toplasmic domain of uvomorulin [86]. Another CAM, a prototype
of class IT cadherin, is K-cadherin specifically expressed in the
kidney, which mediates Ca2 -dependent homophilic cell aggrega-
tion [87]; its role in nephrogenesis remains to be investigated.
Tensin is another newly discovered protein that binds to F-actin
and is expressed in the kidney; however, it regulates the postnatal
renal development only [88]. Thus, it is not clear whether or not
the actin binding proteins are essential to the organogenesis of the
embryonic kidney. Other proteins that do not bind to actin, e.g.
Dp140 (a product of Duchenne muscular dystrophy locus), are also
expressed in the embryonic metanephros [89], and there role in
organogenesis needs to be studied.
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Sialoconjugates and glycosphingolipids. Several other cell surface
sialoconjugates, including podocalyxin [30], sialylated glycosphin-
golipids (gangliosides) [481 and many other N-linked oligosaccha-
rides [901 are expressed in the kidney. Podocalyxin may be the
major sialoglycoprotein in the developing glomerular epithelium
involved in podocyte-GBM interactions [301. The gangliosides are
ubiquitously distributed in various tissues, and display cell-cell and
cell-substratum adhesive properties by modulating protein ki-
nase-C and tyrosine kinase activities [91]. Two gangliosides of
interest are GD2 and GD3; the latter is expressed on well-
differentiated podocytes, metanephric mesenchyme and intersti-
tial cells near the stalk of the ureter. Since GD3 is expressed at the
cell surfaces and its antibodies markedly inhibit tubulogenesis,
this suggests that cell:cell contact in epithelial:mesenchymal inter-
actions is crucial for metanephric development [48].
GROWFH FACTORS AND THEIR RECEPTORS
In recent years, a conjoint role for ECM glycoproteins and
growth factors in organogenesis has been increasingly recognized
[1]. The ECM glycoproteins, such as PGs, may bind and act as
storage depots for certain growth factors, such as fibroblast
growth factor (FGF) and transforming growth factor (TGF-f3),
and modulate their biological activities [641. Since the growth
factors are known to modulate the expressions of ECM glycopro-
teins, it seems that the biology of ECM and growth factors is
intricately linked to cellular differentiation and morphogenesis.
Growth factors are polypeptides that modulate a wide variety of
biological processes, including cell proliferation, cell differentia-
tion, cell migration and ion transport [92] in an endocrine or
paracrine/juxtacrine manner [93]. Within the same family, they
may have opposing effects, for example, TGF-f3 inhibits [94] while
TGF-cs promotes cellular differentiation [95]. They elicit biologi-
cal responses by binding with the specific receptors with trans-
membrane tyrosine or serine/threonine kinase catalytic domains
[10, 11], with a few exceptions, such as insulin-like growth factor-TI
(IGF-II). The tyrosine kinase receptor family includes several
members, and each member is made up of a large glycosylated
extracellular ligand binding domain, a transmembrane hydropho-
bic region and an intracytoplasmic domain with tyrosine kinase
catalytic activity. The latter domain is highly conserved and is
auto-phosphorylated following homo- or hetero-dimerzation and
binding of various ligands, such as IGF-I and TGF-a. The
serine/threonine kinase receptors, mainly utilized by the TGF-/3
family of growth factors, include type-T and -II, and their intra-
cellular catalytic domains similarly are phosphorlyated following
ligand binding and dimerization. The same receptor can be shared
by different ligands or growth factors, although their affinities may
differ. For example, insulin shares receptors with IGF-1, and
epidermal growth factor (EGF) with TGF-a [10, 11]. Following
phosphorylation of the receptor, there is an activation of mem-
brane bound phospholipase-C, increased phospho-inositol metab-
olism and stimulation of ion, sugar and amino acid transports, and
activation of various nuclear events, which eventually modulate
cellular growth, proliferation and differentiation. Thus, in princi-
ple, any receptor with kinase activity, or alternatively, any ligand
that binds to such a receptor has the potential to regulate
growth-related activities. The fact that the various growth factors
and their receptors are spatio-temporally expressed during orga-
nogenesis suggests an active participation in various developmen-
tal processes [5]. The various growth factors and their receptors
that may play a role in metanephrogenesis include insulin, IGF-I
and IGF-II [96—100], TGF-a and TGF-13 [94, 95], leukemia
inhibitory factor (LIF) [101], EGF [102], platelet-derived growth
factor (PDGF) [103], nerve growth factor (NGF) [104, 105] and
hepatocyte growth factor (HGF) [106, 1071 and glial cell-derived
neurotropic factor (GDNF) [108, 109]. Finally, transferrin, a
carrier protein, although not a conventional growth factor, is
"essential" for in vitro growth of the metanephros [110]. Interest-
ingly, the retinol compounds, which are not polypeptide growth
factors, also have been shown to promote metanephric growth
[1111.
Insulin-like growth factor-I (IGF-I) and IGF-II, insulin and
their receptors
The TGFs or somatomedins are made up of single polypeptide
chains with 70 (IGF-I) or 67 (IGF-IT) amino acids [112]. They
were known as "sulfation factors" in the past since they stimulate
the synthesis of sulfated proteoglycans (PGs). They are primarily
synthesized by the liver, and circulate in plasma non-covalently
attached to several IGF-binding carrier proteins; the latter either
suppress or accentuate their biological activities. The biological
activities of IGFs depend upon their concentrations in the tissues,
where they bind to their putative receptors and regulate growth in
a paracrine or autocrine manner. The IGF-I receptor (IGF-IR),
like that of insulin, is a tetrameric glycoprotein with two a and /3
subunits, the latter containing tyrosine kinase domains. IGF-IR
also has the capacity to bind both insulin and IGF-II, although the
latter with much less affinity. The IGF-II receptor (IGF-IIR) lacks
a tyrosine kinase domain, and is homologous to the mannose-6-
phosphate receptor, which is involved in the translocation of
nascent enzymes to the lysosomes [1121.
During murine embryonic development, IGF-I mRNA expres-
sion is detectable by day 11, and rises eight- to ninefold over the
following two days. While the levels of IGF-II mRNA remain
constant, however, the levels of both fall precipitously following
birth [113, 114]. IGF-II is expressed in the undifferentiated
mesenchyme, while TGF-I is seen on the collecting ducts, the
anlage of ureteric bud branches. Although TGF-IR is expressed by
both cell types of the metanephros, it is mainly concentrated on
the ureteric bud epithelium. This differential expression may be
well suited for cell:cell-ligand:receptor interactions in a paracrine
manner. A similar paracrine mechanism may be operational in
mature kidneys where the receptor, IGF-TR, is expressed on the
basolateral aspect of the proximal tubular epithelium and the
ligand, that is, IGF-I, is synthesized in the adjoining collecting
ducts [113, 114].
The role of IGFs in metanephrogenesis was elucidated by
studies with antisense oligonucleotides and antibodies [96—100].
Addition of anti-IGF-T or -II antibodies to the organ culture
medium resulted in growth retardation of the metanephroi [961.
Conversely, exposure to IGF-I induced a trophic response in vitro
(Fig. 4, C vs. D) with increased 3H-thymidine incorporation and
an accentuated synthesis of PGs, suggesting a relationship be-
tween lOF and ECM glycoproteins [99]. The role of IGF-I was
further elucidated by translational blockade of its receptor using
antisense oligonucleotides [97, 98], which induced marked atro-
phy of the metanephroi (Fig. 4, E vs. F). Similar results were
obtained following translational blockade of the insulin receptor
[99, 100]. Data on the effect of blockage of the IGF-II receptor are
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not available. However, IGF-II-deficient mice exhibit normal
development of the kidneys [115]. Similarly, mice carrying single
or double mutations, that is, IGF-I', IGF-IR , IGF-I'/
IGF-II, IGF-I/lGF-IR ' or JGF-II /IGF-IR', re-
vealed no metanephric defects, although some animals died in utero
[116]. It is conceivable that in gene-disrupted mice other growth
factors assume biological activities to compensate for those factors
that are deficient.
Epidermal growth factor (EGF) family and their receptors
The EGF family includes EGF, transforming growth factor-a
(TGF-a) and vaccinia growth factor (VGF) [117]. EGF is a 53
amino acid polypeptide produced mainly by the salivary gland and
kidney. The urinary excretion of EGF or "urogastrone" is related
to its expression and production in the lower nephron, while the
plasma concentration is proportional to its synthesis by platelets,
which may primarily determine its biological effects at various
target sites. EGF exerts its effects by binding to its putative
tyrosine kinase receptor, which it shares with TGF-a. The trun-
cated form of the receptor has homology with the avian erythro-
blastosis viral oncogene (v-erb-B) product [118]. EGF transcripts
are produced only during the post-natal period, while the expres-
sion of TGF-a has been detected in mid- and late-gestation
embryos, and therefore TGF-a is regarded as an embryonic form
of adult EGF. TGF-a is seen in the mesonephric tubules at day 9
or 10, while the EGF receptors appear by day 11 in mice embryos
[119]. Similar to the trophic effect in other systems, addition of
EGF to the metanephric culture medium results in hypertrophy of
the fetal kidneys, an increased synthesis of DNA in tubular
epithelia and cyst formation; however, glomerular differentiation
is inhibited [120]. Conversely, exposure to anti-TGF-a results in
dysmorphogenesis of ureteric bud branching and poor metaneph-
nc growth [95]. In an another study, EGF in concert with pituitary
extract and ECM matrix, especially type IV collagen, promoted
tubulogenesis of rat but not of mouse metanephric blastema [121].
Lastly, EGF or TGF-a induced tubulogenesis of baby kidney cells
of mice in matrigel, thus affirming their role in metanephric
development [122].
Transforming growth factor-j3 superfamily and their receptors
The transforming growth factor-n (TGF-f3) superfamily family
constitutes a large number of bifunctional regulatory proteins
which can be subclassified into four to five subfamilies [123]. The
first group is made up of structurally-related dimeric polypeptides
with considerable amino acid sequence homology, and includes
TGF-p1. The second group with distantly-related polypetides,
include activins/inhibins, decapentaplegics (dpp), bone morpho-
genetic proteins (BMPs), growth differentiation factors (GDFs),
glial-denived neurotropic growth factor (GDNF), and others like
Mullerian inhibiting substance (MIS) and Vgl with its related
Vg2R. TGF-pl consists of two disulfide-bonded identical
polypeptide chains of 112 amino acids, and has diverse activities,
including stimulation/inhibition of proliferation, initiation/sup-
pression of differentiation and promotion/retardation of cell
migration. These activities of TGF-f31 depend upon the type of
tissue, an autocrine versus a paracrine mode of action, the type of
receptor activation, and the matrix proteins involved [124].
TGF-pl is expressed in the metanephric mesenchyme and the
epithelial-mesenchymal surface [94], and its effect is mediated via
interactions with type I and type II serine/threonine kinase
receptors [1241, conceivably, present in the ureteric bud epithe-
hum. Besides these receptors, TGF-j31 also binds to cell-bound
betaglycan and ECM decorin, which re-emphasizes the functions
of PGs as storage depots for growth factors [641. The bound
decorin may neutralize the biological activity of TGF-J3 by com-
peting with the type I or type II receptors. Since TGF-pl is known
to stimulate the synthesis of various ECM proteins, including
decorin, this suggests that decorin acts through a negative feed-
back system to regulate TGF-pl activity and cell growth, as
observed in mammary gland morphogenesis [125]. Similarly, the
addition of TGF-f3 to the culture medium has been shown to
inhibit metanephric growth and differentiation of glomeruli, prox-
imal tubules and collecting ducts [94]. Contrawise, exposure of
anti-TGF-f31 accelerates tubulogenesis of the metanephric blast-
ema [91. TGF-f3 also perturbs the tubulogenesis of MDCK cells
grown in collagen gels [126], which may be due to the increased
synthesis and deposition of ECM proteins that hinder the migra-
tion of the advancing tubular epithelial tips. These in vitro studies
suggest a negative regulatory effect of TGF-pl on renal organo-
genesis, but such effects could not be elucidated in TGF-/31-
deficient mice, even though defective yolk sac vasculogenesis and
hematopoiesis were quite apparent [127].
Within the TGF-j3 superfamily, other members relevant to
renal morphogenesis include bone morphogenetic proteins
(BMP5) and glial-denived growth factor (GDNF) [123]. BMPs are
synthesized as large precursors, and after proteolytic cleavage
mature into protein dimers, which can induce bone formation in
chondrocyte cultures [128]. BMPs 3 to 7 are expressed in the
embryonic kidney; BMP7 transcripts are initially detected in the
mesenchyme and subsequently in the epithelial elements of the
nephrogenic zone. Interestingly, BMP7-deficient mutant mice
exhibit hypogenesis/agenesis of kidney, eye and skeletal system
[129, 1301. Although BMP7 apparently plays a role in nephrogen-
esis, it does not disrupt early inductive tissue interactions. Coin-
cidentally, the expression of other markers of nephrogenesis, such
as c-ret, Pax-2 and Wnt-4, is also reduced in BMP7-deficient mice
[129, 1301.
GDNF shares the pattern of seven regularly spaced cysteines
found in other members of the TGF-f3 superfamily, and is a
glycosylated disulfide-bonded homodimer with Mr 32 to 42 kDa
[123]. This factor promotes survival and differentiation of a
number of central and peripheral neurons, and, conceivably, its
neurotropic effects are mediated via a tyrosine kinase receptor
protein encoded by the c-ret proto-oncogene [1081. It is highly
expressed in the metanephnic mesenchyme, and such a strategic
location of GDNF in the blastema is well suited for its paracrine
mode of interaction with its receptor, c-ret, distributed on the tips
of uretenic bud branches, Interestingly, GDNF-null mice, gener-
ated by homologous recombination in embryonic stem cells, not
only have an absence of enteric neurons but also show agenesis/
dysgenesis of the kidneys [109], suggesting a critical role of
neuronal tissues-derived factors in metanephric development.
Heparin-binding growth factors and their receptors
Another set of growth factors that are distributed in association
with ECM proteins include acidic and basic fibroblast growth
factors (aFGF/FGF-i and bFGF/FGF-2), which are endowed with
mitogenic, angiogenic and differentiation activities [131]. The
aFGF and bFGF lack signal peptides, and consist of single
polypeptide chains with 50% homology, and contain 140 and 146
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amino acids, respectively. In the extracellular space, bFGF inter-
acts with the GAG chains of syndecan and perlecan or with
heparin N-sulfated oligosaccharides. This facilitates its binding to
the receptor (FGF-R), which induces phosphorylation of tyrosine
kinase catalytic domains and modulation of distal signaling events
[132]. FGF-2 can also mediate transcriptional activation of WTJ
and c-met genes and induce tubule formation in the uninduced
mesenchyme in concert with pituitary extract in vitro [133]. Since
FGFs are found complexed with endothelial products, that is,
heparin or heparan sulfate, they can be envisioned to modulate
events related to angiogenesis [134]. Moreover, they are chemo-
tactic for endothelial cells and induce synthesis of plasminogen
activators, collagenases and other proteases-events conducive to
the formation of new blood vessel sprouts. The fact that the
kidney produces FGFs or growth factors with heparin binding
affinity suggests that they have a role in vascularization of the
developing metanephros [135], and indeed, in chimeric experi-
ments, these agents augmented angiogenesis of the quail cho-
rioallantoic membrane capillaries with vascularization of the
metanephric graft [16, 17].
Other macromolecules that bind to heparin and regulate epi-
thelial:mesenchymal interactions during development include
midkine (MK) and pleiotrophin, which are co-distributed with
syndecan-1 [136]. Both MK and pleiotrophin are mainly expressed
in the epithelial elements of the embryonic kidney, and thus they
may play a role in renal development. Although anti-MK neutral-
izing antibody inhibits tooth development, it does not disrupt
morphogenesis of salivary gland and kidney, suggesting a func-
tional redundancy of MK in metanephrogenesis [137].
Platelet-derived growth factor (PDGF) and its receptor
Besides platelets, PDGF is synthesized by a number of cells,
including macrophages, endothelial and embryonic cells and
transformed cell lines [138, 139]. It is a dimeric protein with A and
B polypetide chains and three isoforms, AA, BB and AB. Inci-
dentally, the products of oncogene v-sis are homologous to the B
chain. The putative tyrosine kinase receptor of PDGF contains a
and f3 subunits that possess variable binding affinities to the
isoforms of PDGF, capable of at least six different coupled
ligand-receptor interactions and a wide range of biological activ-
ities mediated in an autocrine or paracrine fashion [138, 139].
During nephrogenesis, PDGF is expressed in the epithelia of early
vesicle and S-shaped bodies, and in the glomerular mesangium,
whereas its 13 subunit receptor is expressed in the undifferentiated
mesenchyme, vasculature, interstitial cells and in the mesangium
of mature glomeruli [103]. Conceivably, co-expression of the
ligand and receptor in adult kidney suggests that PDGF facilitates
the recruitment of mesangial precursor cells from the adjacent
interstitium. This recruitment may facilitate the maturation of
nephrons since PDGF also modulates endothelial functions and
actively enhances the synthesis of various ECM proteins, the
integral components of the glomerular capillaries. This is sup-
ported by studies in mice deficient in PDGF-B or PDGF-f3R that
show an absence of mesangial cells, but preservation of endothe-
hal cells in the glomerulus [140].
Nerve growth factor family and their receptors
Nerve growth factor (NGF) plays a vital role in various
neuronal and non-neurological-embryological functions, and ad-
ministration of anti-NGF antibodies is known to induce neuro-
sensory and -sympathetic deficits [141]. NGF was originally iso-
lated from salivary glands, and is a trimer complex of A, B and Q
subunits with a M '-S- 130 kDa. Other members of the NGF family
include brain-derived neurotrophic factor (BDNF), NT-3, -4 and
-5, and their biological effects are elicited by binding to high or low
affinity tyrosine kinase receptors, encoded by the trk family of
proto-oncogenes. A transmembrane protein, known as p75 LNGFR
binds to all the known members of the neurotrophin family with
low affinity [142]. trkA is a low affinity receptor for NGF, but its
co-expression with p75LNGFR leads to high affinity binding. trkB, a
high affinity receptor, is activated by BDNF, NT-3 and -5, and trkC
by NT-3. A hybrid receptor (trklc-ros) transmits c-ros-specific
signals in response to activation by NGF. The interest in the role
of NGF and its receptors stems from the experiments suggesting
that spinal cord tissue [42] and embryonic neurons [1431 are
potent inducers of metanephric differentiation, as well as from
their presence in kidney tissues [141]. NGF and its receptors are
expressed in the collecting tubules and glomerulus, respectively.
The low-affinity NGF receptor (p7SLNGFR), is expressed in the
uninduced mesenchyme and developing podocytes of the S-
shaped stage glomeruli [105]. trkB is expressed in the cortical
mesenchyme that differentiates into stromal cells, and trkC is
expressed in the medullary collecting ducts. Relevant to the role
of NGF and its receptor in renal development, p75LNGFR anti-
sense oligodeoxynucleotide inhibits ureteric bud branching mor-
phogenesis [104], while sense oligodeoxynucleotide has a minor
effect [105]. Such renal deficits are not observed in vivo in mice
lacking p75LNGFR [142], however, this does not negate the
relevance of neurotrophic factors in metanephric development
since GDNF-deficient mice show hypogenesis of the kidney (vide
supra).
Proenkephalin A (PEA) is another recently discovered neu-
ropeptide that is expressed during development in mesodermal
lineage cells [144]. PEA mRNA and its encoded peptide, met-
enkephahin, are transiently expressed in the developing kidney,
and its role in nephrogenesis remains to be investigated.
Hepatocyte growth factor/scatter factor and its receptor
Hepatocyte growth factor (HGF) is present in the the sera of
rats with hypertrophy of the liver in response to partial hepatec-
tomy, and it is identical to a mesenchymal cell-derived scatter
factor (SF) [145]. HGF/SF is a heterodimeric complex of a and p
subunits, and is characterized by triple disulfide loop structures,
known as kringles. Subsequent to its cleavage by urokinase
plasminogen activator (u-PA), HGF/SF binds to its putative
tyrosine kinase receptor, encoded by the c-met proto-oncogenc
[146]. The receptor is a heterodimer with a and f3 polypeptide
chains, and the extracellular binding and tyrosine kinase domains
are confined to the 13-chain. The biological activities of HGF/SF
are quite diverse and include dispersion, motility, migration and
proliferation of epithelial cells and effects on morphogenesis
[145]. The dispersive activity of HGF/SF may be related to
up-regulation of the activity of one of the ECM-degrading en-
zymes, such as urokinase (u-PA) [73]. However, it is the morpho-
genetic properties of HGF/SF that regulate renal tubulogenesis,
define polarity characteristics, and modulate mammary gland
ductulogenesis [147, 148]. HGF/SF and c-met are co-expressed in
the metanephric mesenchyme [149], whereas c-met is exclusively
expressed in the ureteric bud [107], suggesting they play a role in
renal development via a juxtacrine mode of interaction. Indeed,
598 Kanwar et al: Metanephric development
anti-HGF antibodies inhibit the formation of epithelial conden-
sates and ureteric branching morphogenesis in metanephroi [106,
107], and the development of tubules in MDCK cells [147]. The
role of HGF/SF as an inducer of differentiation was indirectly
suggested by the experiments in which its addition to a metaneph-
nc mesenchyme ridge (MMR) cell line led to an increased
expression of uvomorulin, an epithelial cell adhesion molecule,
while the expression of N-CAM was reduced [150]. Although
these in vitro data are provocative, the role of HGF/SF in renal
development is not supported by knock-out experiments in mice
[1511.
Leukemia inhibitory factor
Leukemia inhibitory factor (LIF) is a glycoprotein with a Mr
43 kDa, which modulates the growth and differentiation of many
pluripotent cells [152]. During development, at low doses it
enhances the arborization of the ureteric bud branches, while at
higher concentrations it reversibly blocks the induction of the
metanephric blastema so that very few mature nephrons develop,
even though epithelial condensates, expressing laminin, are
formed normally from the pre-existing induced mesenchyme
[1011. These observations suggest that LIF perturbs the epithelial:
mesenchymal interactions, and that it has a dual regulatory effect
on the morphogenesis of the kidney.
In addition to the growth factors described above, a number of
others require further study. It should be stressed that all the
known soluble growth factors are individually incapable of induc-
ing differentiation of metanephric mesenchyme into an epithelial
phenotype capable of proliferation [102]. Thus, to gain further
understanding of the metanephric development, the emphasis of
recent investigations have shifted from growth factors to a more
aggressive proliferative process, that is, carcinogenesis, in which
oncogenes, suppressor- and proto-oncogenes play an essential
role.
PROTO-ONCOGENES, TRANSCRIPTION FACTORS AND
SUPPRESSOR GENES
During mesenchyme to epithelium conversion, ECM macro-
molecules transmit inductive differentiation signals, following
which replication proceeds under the influence of various growth
factors [153, 1541. Besides growth factors, the replication of the
differentiated cells could be regulated by factors active during the
proliferation of neoplastic cells, such as proto-oncogenes or
transcription factors. Certain proto-onocogenes may directly in-
fluence differentiation events, such as by Wnt; the term is an
amalgam of the wingless (wg) and mt genes [1551. Thus, it appears
that differentiation and replication events are intricately linked.
The role of oncogenes in growth stems from transfection studies,
such as normal NIH3T3 cells infected with proto-oncogenes,
exhibited accelerated growth and acquisition of tumorigenic po-
tential [156]. Furthermore, several proto-oncogenes, such as
c-bek, c-erh, c-fos, c-jun, c-max, c-met, c-mos, c-myc, c-myclc-max,
c-neu (c-erb B2), c-ras, c-ret, c-ros, c-sis, c-src and c-trk, display a
well-defined spatio-temporal expression in various embryonic
tissues, suggesting that they have a potential role in the early
stages of mammalian development [1571.
Proto-oncogenes related to the family of tyrosine kinase
receptors
A number of proto-oncogenes transduce signals across the
plasmalemma, and initiate a variety of intracellular events that
ultimately affect nuclear transcription [10, 11, 1181. Basically, the
signal transduction is accomplished by protein products of the
oncogenes, termed onco-proteins, which serve as high or low
affinity receptors for ligands or growth factors. As indicated in the
previous section, such growth factor receptors constitute trans-
membrane proteins containing intracytoplasmic domain that are
endowed with intrinsic kinase catalytic activity for tyrosine phos-
phorylation. Following tyrosine phosphorylation, certain intracel-
lular proteins are translocated to the nucleus, bind to DNA and
enhance transcription and replication of cells. As in many tumors,
the proto-oncogenes and their ligands may be co-expressed in
certain embryonic tissues, such as, HGF/SF and c-met in the heart,
condensing somites and neural crest cells, suggesting an "auto-
crine" mode of interaction [158]. At times, the ligand:receptor
interaction may be mediated in a "paracrine" or "juxtacrine"
fashion, as exemplified by the expression of c-ret in the ureteric
bud epithelium and its putative ligand GDNF in the metanephric
mesenchyme [108, 109]. This scenario is an apparent recurring
theme in metanephric epithelial:mesenchymal interactions medi-
ated via the tyrosine kinase family of receptor proteins, including
the products of a large number of proto-oncogenes, that is, c-erb,
c-erb B2 (c-neu), c-met, c-ret, c-ros and c-trk. Among these, the role
of c-erb, c-met, and c-trk have been discussed in the previous
section, and thus, only the c-ret, c-ros, c-neu and Src family of
tyrosine kinases will be reviewed in the following section.
The proto-oneogene c-ret, a prototype of receptors for EGF
(c-erb B2), NGF (c-trk), HGF/SF (c-met) and the Steel factor
(c-kit), is an instructive example to understand the basic signaling
pathways mediated by receptor tyrosine kinases that are essential
for epithelial:mesenchymal interactions in metanephric develop-
ment [159, 160]. The c-ret encodes a single transmembrane
polypeptide with Mr —420 kDa, kind certain of its isoforms are
expressed in various tissues [161]. The extracellular segment of
the polypetide contains motifs with sequence homolgy to cad-
herins, suggesting Ca2 h-dependent homophilic interactions of the
proto-Ret molecules. Binding to its putative ligand, GDNF, leads
to the phosphoiylation of Ret protein [108, 109]. Interestingly,
phosphorylation also can be induced by other growth factors, such
as TGF-a, IGF-I and HGF [162]. c-ret was originally discovered in
patients with multiple endocrine neoplasia (MEN) types hA and
JIB [163], and its expression is confined to the developing sensory
and autonomic neurons and genito-urinary systems. In the devel-
oping mouse metanephros, c-ret is expressed in the Woiffian duct
at days 8.5 to 10.5, in the ureteric bud epithelium at day 11.0 to
11.5, and in the growing tips of the collecting ducts at days 13.5 to
17.5. Its constitutive expression in both the renal and neural
tissues (the latter a known inducer) stimulated investigation of its
role in metanephric development [159]. A targeted mutation in
the mouse c-ret locus (ret-K ) led to the deficiency of enteric
neurons and varying degrees of hypoplasia or aplasia of the
kidneys and ureters [160]. Interestingly, no abnormalities were
observed in the adrenal glands, suggesting that the biological
functions of c-ret differ in the human versus mouse. More recently,
in vitro co-culture experiments utilizing ret-K or ret-K mesen-
chyme and epithelium suggest that renal hypoplasia is due to the
defects in the ureteric bud, where c-ret is expressed prior to
induction [164].
c-ros, originally isolated from UR2 sarcoma virus, encodes a
transmembrane protein with a predicted Mr —260 kDa prior to
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post-translational modification [165]. It is regarded as the mam-
malian homologue of the gene product of sevenless from Drosoph-
ila [166]. The term "sevenless" refers to its ligand, the protein
product of bride of sevenless (boss), which spans the plasmalemma
seven times, and is involved in the differentiation and morpho-
genesis of the compound eye of Drosophila. c-ros is transiently
expressed during mouse embryogenesis, and its transcripts, like
c-ret, have been localized to the tips of the ureteric bud branches
[167], suggesting a role in epithelial:mesenchymal interactions in
a "paracrine" manner while the ligand, although not well-charac-
terized, would be expressed in the mesenchyme [165]. The role of
c-ros was elucidated by in vitro experiments, where an inhibition of
the ureteric bud branches and nephron formation was induced by
inclusion of specific antisense oligos into metanephric culture
medium [105, 168]. However, the c-ros - male mice showed
urogenital abnormalities confined only to epididymis [169].
The c-erb B2, a related EGF receptor, is a homologue of the rat
c-neu gene [170, 171], and a single point mutation in the latter
renders it highly oncogenic [172], c-erb B2 encodes a 185 kDa
transmembrane protein. The receptor protein is mainly expressed
in respiratory, intestinal and renal epithelia, with higher levels of
expression in embryonic than adult tissues. Its putative ligand is a
soluble protein with Mr - 44 kDa that contains immunoglobulin
and EGF sequence domains [173], which can induce tyrosine
phosphorylation of c-neu, and subsequent proliferation or differ-
entiation, as in breast carcinoma cell lines. To stress its differen-
tiation activity, the ligand has been named neu differentiation
factor (NDF); an alternate name is heregulin (HRG) [174]. The
expression of NDF in the mesenchyme surrounding epithelia and
c-erb B2 in the epithelium are well-suited for paracrine interac-
tions and a potential role in nephrogenesis [9]. Interestingly,
over-expression of c-erb B2 in transgenic mice results in epithelial
hyperplasia and pre-neoplastic lesions in kidney and lungs [175].
The other tyrosine kinase proto-oncogenes expressed during
development belong to the Src family, and they include src, n
and yes. A deficiency of these genes, individually, does not
adversely affect renal morphogenesis. However, in fynlyes double
mutant mice, post-natal degenerative changes and glomeruloscle-
rosis were noted in the kidney [176]. However, the question as to
which of these proto-oncogenes is most critical in nephrogenesis
remains to be addressed. The effect of antisense deoxyoligonucle-
otides with sequences derived from the phosphotyrosine domains
of a number of proto-oncogenes, that is, c-ret, c-ros, c-met, c-neu,
c-trk and c-erb, was assessed on the renal explants. Notable effects
were observed only with c-ret (Fig. 4, G vs. H), suggesting a
significant role for c-ret in metanephric development [160, 162,
164].
Proto-oncogenes/transcription factors
in addition to the tyrosine kinase receptors, there are other
intracellular mitogen-activated protein kinases (MAPKs) that
modulate growth signals transmitted to the nucleus [177, 178].
During this signaling process, two distinct groups of cellular genes
are induced. The first group, immediate-early genes (lEG), are
induced in the absence of protein synthesis, whereas the second
group, late growth-regulated genes, are dependent on protein
synthesis. Included in the lEG group are a number of proto-
oncogenes, such as c-myc, c-jun and c-fos, and the recently
discovered early growth response (EGR) family of genes [179].
All the proto-oncogenes and EGR genes encode various tran-
scription factors, which bind to targeted DNA sites and modulate
cell proliferation. The myc proto-oncogene family, that is, c-myc,
L-myc and N-myc are expressed at high levels in the whole mouse
embryo and in regenerating liver in partially hepatectomized rats,
suggesting they play a role in normal growth and differentiation
[180, 181]. Following translation, the c-myc onco-protein is rapidly
transported into the nucleus where it heterodimerizes with the
protein product of c-mw. The c-myc/c-max complex binds to
specific DNA sequences and activates growth promoting genes
[182]. Conceivably, the process of heterodimerization is also
applicable to other lEGs, such as between c-jun and c-fos [179].
Among the lEGs, the myc family of proto-oncogenes have been
thoroughly investigated in metanephric development [1831. c-myc
mRNA is strongly expressed both in the uninduced and induced
mesenchyme in the peripheral and middle cortex of the metane-
phros of the 16-day embryonic mouse. N-myc expression is low,
and is localized in scattered clusters in the outer cortex. Interest-
ingly, L-myc is mainly expressed in the epithelia of ureteric bud
branches. These studies suggest that c-myc is involved in the early
proliferative phases of metanephric development. The biological
role of the myc family of proto-oncogenes in renal development
was elucidated by insertional mutagenesis and homologous re-
combination experiments. The animals homozygous for N-myc
showed slightly reduced morphogenesis of mesonephric tubules
[1841. In contrast, the results of c-myc insertional mutagenesis
studies were quite dramatic. A fusion construct was generated by
linking a noncoding DNA segment of mouse-mammary tumor
virus (MMTV) with mouse c-myc. The transgenic mouse carrying
the MMTV-myc recessive mutation developed aplasia or hypo-
plasia of one or both kidneys and limb deformities (Id) [185, 1861.
The recombinant proteins of this chimeric limb-deformity (ld)
gene are referred to as "formins," whose action is variable in
different tissues during development [187]. The nuclear expres-
sion of the so-called "formins" is restricted to the pronephros and
mesonephros, suggesting a role only in the very early develop-
mental processes.
Other signaling proteins relevant to metanephric development
are encoded by Wnt genes. Some are expressed in the kidney, such
as Wnt-4 [188], while others are not expressed, such as Wnt-1
[189], but play a vital role as inducers in the differentiation of
metanephric mesenchyme. For example, metanephric mesen-
chyme differentiates into a tubular epithelial phenotype, express-
ing E-cadherin, when co-cultured with NIH3T3 fibroblasts retro-
virally transfected with Wnt-1 eDNA and secreting Wnt-1 protein
[1891. These results are reminiscent of the data of experiments in
which the spinal cord was used as an inducer [42, 43]. Interest-
ingly, Wnt-1 mRNA is expressed in thespinal cord, suggesting that
Wnt-1 protein may be one of the constituents of spinal cord that
dictates inductive conversion of the metanephric mesenchyme.
The results of experiments with Wnt-4, are equally interesting.
Wnt-4 is expressed in the metanephric mesenchyme and its early
derivatives, that is, comma and S-shaped bodies. Wnt-4 mutant
mice failed to form pretubular cell aggregates, suggesting a defect
in mesenchymal-to-epithelial conversion. In addition, there was a
loss of expression of other transcription factors, that is, Pcix-2 and
Pax-8. Interestingly, loss of expression of Wnt-4 has also been
observed inBMP-7 mutant mice with urogenital abnormalities
[129, 130], reinforcing the relevance of Wnt-4 in renal develop-
ment. Like BMP-7, other ECM proteins also lose their co-
expression with the loss of Wnt mRNA. For instance, interference
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in the de novo synthesis of the proteoglycans, the known morpho-
genetic modulators, is associated with the loss of expression of
Wnt-1l mRNA at the tips of the ureteric bud branches of the
embryonic metanephros [190].
Other transcription factor genes expressed during early renal
differentiation include homeobox (Hox) [1911 and paired-box
(Pox) [192, 193]. Interest has been focused on the Pox gene since
Krd (kidney retinal defects) mice with deletion of the Pax-2, and
spontaneous mutation at the Sd locus present in the vicinity of the
Pax-8 gene in Danforth's short tail (Sd) mice are accompanied by
renal abnormalities [194, 195]. Similarly, transgenic mice over-
expressing Pax-2 exhibit disorganization of renal epithelial struc-
tures [193]. Intriguingly, Pax-2 translational blockade by antisense
oligodeoxynulotide in vitro results in the failure of mesenchymal
cell aggregation and conversion into epithelial condensates, indi-
cating an important influence during metanephric differentiation
[192]. Both Pax-2 and Pax-8 genes are expressed in induced
mesenchyme and early derivatives thereof, but never in the
blastema. Although Pax-5 has high sequence homology with Pax-2
and Pax-8, it is not expressed in the kidney [196]. Even though
Pax-2 is absent in the mesenchyme, gene disruption of BF-2, a
specific transcription factor for stromal cells, is associated with
loss of expression of Pax-2 in tubular elements and with severe
renal abnormalities, re-emphasizing the significance of epithelial:
mesenchymal interactions in renal development [197]. Compared
to Pax-8, Pax-2 appears earlier during development in comma-
shaped bodies, ureteric bud branches and its derivatives, that is,
collecting tubules, while the expression of Pax-8 persists longer in
S-shaped bodies before being down-regulated as the nephron
elements matures. The progression of Pax-2 to Pax-8 expression in
the induced mesenchyme seems to require the Wnt-4 gene [188],
suggesting that nephrogenesis is a multi-step process involving
interactions between trasncription factors and cell-signaling mol-
ecules. An example of gene interactions is the repression of
transcription of Pax-2 by the WiIm's tumor (WT-1) suppressor
gene. The latter binds to Pax-2 regulatory sequences upstream of
the initiation codon in exon 1 [198]. Interestingly, Pax-2 can be
transcriptionally activated by binding of EGR-1 to its promoter
region for the WT-1 recognition sites, suggesting that its activity is
modulated by EGR-1 and HIT-i [199]. Furthermore, Pax-8 can
transactivate the HIT-i suppressor gene and its expression [200].
The Hox family include a number of genes that are expressed in
embryonic and adult kidney tissues with an apparent concentra-
tion gradient in the medulla and cortex. Such gradients of
expression are also seen in whole embryos where they are involved
in regional specifications and patterning in the axial skeletal
system. In this regard double mutant mice lacking Hoxa-li and
Hoxd-ii, genes normally expressed in the rnetanephric blastema,
not only suffer from skeletal deformities but also have severe renal
malformations [1911. The relevance of other homeoproteins ex-
pressed in the kidney, including hepatocyte nuclear factor-1c and
-1/3, await further investigations.
Suppressor genes
The suppressor genes were discovered by somatic cell genetic
experiments in which fusion of tumorigenic and non-tumorigenic
cells resulted in a selective loss of neoplastic growth potential, but
with the retention of certain properties of the cancerous cells
[201]. The suppressor genes encode proteins that usually repress
transcription and inhibit cell growth. In certain instances, they
may activate transcription as well. Thus, basically, they are
transcription factors or nuclear proteins that negatively or posi-
tively regulate cell growth. The deletion of putative suppressor
genes or "anti-oncogenes" is associated with several forms of
cancer in humans. The application of restriction fragment length
polymorphism (RFLP) analyses of various neoplastic cells has led
to the discovery of a number of suppressor genes in humans,
including Rb, p53, HIT-i, NF-i, APC, DCC and VHL [201]. The
genes relevant to the present discussion are p53 and HIT-i [202,
2031, which have potential functional interactions with one an-
other, in that WT-i enhances transcriptional activation by p.53,
while wild-type p53 seems to convert WT-i from a transcriptional
activator to a transcriptional repressor. Conversely, increased
expression of HIT-I induces an increased steady-state level of p53
and stability in its trans-activational properties. Moreover, WT-I
inhibits p53-mediated apoptosis [204], a physiologic process that is
an integral component of metanephric development [205] and
regulated by another set of oncogenes, that is, Bcl-2, BCL-XL, Box
and Bak [206]. Although there is an apparent intricate relation-
ship between these two (HIT-I and p53) suppressor genes, p53
transgenic mice exhibit fulminating apoptosis and hypogenesis of
the kidneys, however, WT-I expression remains normal [203, 207].
HIT-I was discovered in children with Wilms' tumor. It is a
suppressor gene that spans about 50 Kb and has at least four
splice variants [208]. The amino terminus is enriched with proline,
glutamine, serine and threonine residues, the structural motif
found in other DNA binding proteins that regulate transcription
[209]. The carboxy terminus contains KTS (lysine.threonine-
.serine) insertion in the four contiguous cysteine-histidine type
zinc finger domains, which exhibit 70% homology to the early
growth response gene (EGR) family and it binds to a DNA
GC-rich nanonucleotide with the sequence GCGGGGGCG
[209]. Embryologically, the tumor appears to arise in blastemal
cells in the process of differentiation into epithelial forms [210],
and HIT-i is expressed in the induced (condensed) mesenchyme
and in the developing S-shaped bodies and podocytes of the
glomerulus [211]. HIT-i mRNA is detectable during mid gesta-
tion, peaks one to two days after birth, and then declines to adult
levels by the third week [212], suggesting a potential role in
metanephric development. Its role in metanephric epithelial-
mesenchymal interactions is further emphasized in transgenic
mice, where mutation in both the alleles for HIT-i locus
(WT-I) resulted in renal agenesis with failure in the outgrowth
of the ureteric bud [213].
A question to be addressed is the mechanism(s) by which WT-i
regulates renal organogenesis or growth. It may influence other
proto-oricogenes or growth factors and their receptors expressed
within the kidney or the Wilms' tumor. In the latter, N-myc [172],
Pax-2 [214], N-CAM [215], IGF-I 7 [216], IGF-IR [217], IGF-II
[218] and PDGF [219] are expressed, and antibodies to IGF-IR
inhibit the growth of Wilms' tumor transplants in nude mice [220].
Available evidence suggests that WT-i represses transcription of
EGF-receptor, EGR-1, IUF-Il and the PDGF-A and TGF-/31
genes [179, 218, 221, 222]. The prevalent notion is that the IGF-II
is the physiological target for both EGR-1 and HIT-i, the tran-
scription factors that compete for the same DNA binding motif,
5'-GCGGGGGCG-3' [2091. Conceivably, a balance between the
EGR-1 (a positive regulator) and HIT-I (a negative regulator) is
required for metanephric growth to proceed normally [179].
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Finally, a second WT-1 binding sequence (5'-TCCTCCTCCTC-
CTCTCC-3'), noted in the promoters of other growth-related
genes, that is, EGF-receptor, c-myc, Ki-ras, tumor growth factor
133 and insulin receptor, may also be relevant to the regulation of
various developmental processes [223].
CONCLUDING REMARKS
During embryonic life, renal morphogenesis is characterized by
a defined period of intense cellular activity, inductive-transforma-
tion of undifferentiated cells to polarized epithelia, in-growth of
capillaries into an intricate parenchymal epithelial-mesenchymal
mass, and finally the maturation into an organ with diverse
structural and biological functions. A large number of factors are
operative in a defined sequence during nephrogenesis, which are
tightly regulated to attain a successful outcome, that is, the genesis
of functioning nephrons. During the last two decades, using
current sophisticated techniques and ingenious experimental de-
signs, a wealth of information has surfaced that has allowed
greatly expanded insight into the overall cellular events relevant to
renal organogenesis. It should be emphasized that modulation of
the interactions between various ECM glycoproteins, ECM de-
grading enzymes and their inhibitors, CAMs, integrins, growth
factors and their receptors, proto-oncogenes, anti-oncogenes and
transcription factors are required for proper epithelial:mesenchy-
mal interactions essential to successful nephrogenesis. Consider-
able progress has been made, and the roles of such macromole-
cules have been elucidated in renal development over the last few
years. The list is rapidly growing while the roles of others that are
expressed in the kidney require delineation, such as crystallins
(neuro-ectodermal lens proteins) [224], osteopontin (2ar) [225],
SPARC (secreted protein, acidic and rich in cysteine), also known
as osteonectin and BMP-40 [226], epimorphins (mesenchymal
cell-surface proteins) [227], cyclins (cell cycle proteins) [228],
polycystin [229], hedgehog family of proteins [230], and yet to be
described proto-oncogenes and transcription factors. Similarly
under-studied and requiring attention are molecules that regulate
renal vasculogenesis/angiogenesis, which include tyrosine kinase
receptors, fik-1 and ELK, and their putative ligands, VEGF and
LERK-2 [23 1—234]. Also, there are several other novel genes that
have been discovered in the embryonic kidney by differential-
display and -representation techniques [235, 236], and their role in
metanephric development remains to be investigated. Finally,
another area of considerable interest are the macromolecules that
are developmentally regulated in several organ systems and are
involved in apoptosis, such as galectins [237—239]. Apoptosis is an
integral process of embryonic development in which "cells drop
out," and are replaced by other cells to maintain a balance in the
induction and proliferation of more differentiated cells. A "bal-
ance" between the activities of a number of macromolecules,
whether essential or redundant, is an apparent recurring theme
during various steps in development. Such a balance between the
various growth factors, ECM degrading enzymes and their inhib-
itors, and oncogenes and anti-oncogenes is essential to orches-
trate the proper cell signals and responses to assure the progres-
sion of normal organogenesis [240]. In spite of the recent
remarkable progress and the generation of a wealth of data, the
process of renal development is so complex that a clear picture
has yet to emerge of the precise co-ordinated and sequential
events that result in the formation of a mature functioning kidney.
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